<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076851</url>
  </required_header>
  <id_info>
    <org_study_id>IIT-GT0918-CN-1008</org_study_id>
    <nct_id>NCT05076851</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy（ADT）for High Risk Prostate Cancer</brief_title>
  <official_title>A Randomized, Controlled, Double-blind, Single Center，Clinical Trial to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy（ADT）for High Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hongqian Guo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial aims to evaluate the efficacy and safety of neoadjuvant therapy with Proxalutamide&#xD;
      combined with androgen deprivation therapy（ADT）for High risk prostate cancer ，This trial is A&#xD;
      randomized, controlled, double-blind, single center.Treatment cycle is 6 months,&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Proxalutamide: androgen deprivation therapy（ADT）=2:1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response Rate</measure>
    <time_frame>up to 6months</time_frame>
    <description>The proportion of subjects with no morphologically recognizable cancer cell in tumor specimens after radical prostatectomy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Subjects With Minimal Residual Disease</measure>
    <time_frame>up to 6months</time_frame>
    <description>The proportion of subjects that have residual tumors with maximum diameter of 3 mm or less after radical prostatectomy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2</enrollment>
  <condition>Neoadjuvant Therapy \High Risk Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo+ADT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proxalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proxalutamide +ADT</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo+ADT（Androgen Deprivation Therapy） ，Route of placebo administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proxalutamide</intervention_name>
    <description>Proxalutamide +ADT（Androgen Deprivation Therapy） ，Route of Proxalutamide administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD</description>
    <arm_group_label>Proxalutamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must participate voluntarily and sign an informed consent form (ICF),&#xD;
             indicating that they understand the purpose and required procedures of the study&#xD;
&#xD;
          2. Patients must be ≥ 18，male&#xD;
&#xD;
          3. Histopathological by Prostate biopsy confirmed prostatic cancer（No Neuroendocrine&#xD;
             prostate cancer or small cell carcinoma）&#xD;
&#xD;
          4. High-risk prostate cancer (T2c≤ clinical stage ≤T4 or Gleason score ≥8 or PSA≥20ng/ml)&#xD;
&#xD;
          5. Patients willing to undergo laparoscopic radical resection of prostate cancer and&#xD;
             extensive lymph node dissection&#xD;
&#xD;
          6. ECOG PS：0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Imaging or biopsy confirmed distant Metastatic lesion&#xD;
&#xD;
          2. The number of regional lymph nodes metastasis &gt;3&#xD;
&#xD;
          3. Patients had undergone The treatment of Systemic chemotherapy and endocrine therapy&#xD;
             for prostate cancer&#xD;
&#xD;
          4. Patients had undergone prostate surgery、radical radiotherapy or Bilateral orchidectomy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongqian Guo, Phd</last_name>
    <role>Study Chair</role>
    <affiliation>Study Chair Department of Urology, Drum Tower Hospital, Medical School of Nanjing University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongqian Guo, Phd</last_name>
    <phone>+86-13605171690</phone>
    <email>dr.ghq@nju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shun Zhang, Phd</last_name>
    <phone>+86-15050589789</phone>
    <email>explorershun@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Affiliated Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shun zhang, Doctor</last_name>
      <phone>15050589789</phone>
      <email>explorershun@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Junlong Zhuang, Doctor</last_name>
      <phone>15950451917</phone>
      <email>zhuangjl-2008@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</investigator_affiliation>
    <investigator_full_name>Hongqian Guo</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

